Pneumonia, Viral Clinical Trial
Official title:
Remdesivir in Adults With Covid-19: Mansoura University Hospital Experience
COVID-19 is a respiratory disease caused by a new coronavirus (SARS-CoV-2) and causes significant morbidity and mortality. This study is a retrospective trial to assess the efficacy of Remdesivir in adult patients diagnosed with COVID-19 in Mansoura University Isolation Hospital. In this study the investigators will analyze the data collected during treatment.
COVID-19 is a novel respiratory disease caused by coronavirus (SARS-CoV-2) and results in significant morbidity and mortality. To date there is no approved medication for the treatment of patients with COVID-19. Remdesivir is a broad-spectrum antiviral nucleotide analogue that inhibits RNA-dependent RNA polymerase activity among a diverse group of RNA viruses. Non-clinical and clinical data suggest that Remdesivir may be useful for the treatment of COVID-19. WHO has identified Remdesivir as a candidate drug of interest to be studied in clinical trials. This retrospective study is designed to analyze the data collected during the routine care of patients who have benefited from this therapy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04517123 -
Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The "PRONE" Study
|
N/A | |
| Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
| Completed |
NCT01271842 -
Long-term Outcome and Lung Capacity in Survivors of ARDS Due to Influenza A (H1N1) v2009 The RESPIFLU Study
|
N/A | |
| Completed |
NCT04724538 -
Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04414293 -
Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
|
N/A | |
| Completed |
NCT04047719 -
Pneumonia in the ImmunoCompromised - Use of the Karius Test for the Detection of Undiagnosed Pathogens
|
||
| Recruiting |
NCT04528888 -
Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection
|
Phase 3 | |
| Completed |
NCT04606407 -
Inhaled NO for the Treatment of Viral Pneumonia in Adults
|
N/A | |
| Terminated |
NCT04619693 -
Biomarkers for Dexamethasone Response in Sars-Cov-2 / COVID-19 Pneumonia
|
||
| Recruiting |
NCT05077917 -
Cromolyn Sodium for Treatment of COVID-19 Pneumonia
|
Phase 3 | |
| Withdrawn |
NCT04381923 -
COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia
|
N/A | |
| Recruiting |
NCT05976581 -
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients
|
N/A | |
| Active, not recruiting |
NCT04381364 -
Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)
|
Phase 2 | |
| Completed |
NCT04422613 -
Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia
|
N/A | |
| Completed |
NCT04479540 -
Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease
|
N/A | |
| Recruiting |
NCT04474340 -
COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients
|
Phase 1 | |
| Completed |
NCT04424836 -
HFNC Treatment in COVID-19 Pneumonia
|
||
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT04387799 -
Determinants of COVID-19 Pneumonia (MC-19)
|
||
| Completed |
NCT04382547 -
Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells
|
Phase 1/Phase 2 |